Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Curis
CRIS
Curis
FDA Delays And Rivals Will Hinder Progress But Spark Hope
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
18 Aug 25
Updated
18 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$12.00
85.6% undervalued
intrinsic discount
18 Aug
US$1.73
Loading
1Y
-60.1%
7D
6.1%
Author's Valuation
US$12.0
85.6% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$12.0
85.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-63m
25m
2014
2017
2020
2023
2025
2026
2028
Revenue US$25.1m
Earnings US$4.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
42.69%
Biotech revenue growth rate
12.71%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.91%
Calculation
US$4.09m
Earnings '28
x
104.15x
PE Ratio '28
=
US$425.68m
Market Cap '28
US$425.68m
Market Cap '28
/
27.46m
No. shares '28
=
US$15.50
Share Price '28
US$15.50
Share Price '28
Discounted to 2025 @ 8.91% p.a.
=
US$12.00
Fair Value '25
